Structural Mechanisms for the Inhibition of Thrombosis

抑制血栓形成的结构机制

• 批准号: 7090398
• 负责人: JAMES Andrew HUNTINGTON
• 金额: $ 27万
• 依托单位: UNIVERSITY OF CAMBRIDGE
• 依托单位国家: 美国
• 财政年份: 2001
• 资助国家: 美国
• 起止时间: 2001-12-21 至 2010-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7090398
• 关键词: X ray crystallography; activation product; antithrombins; blood coagulation; carbohydrate structure; chemical kinetics; chemical structure; coagulation factor X; cofactor; conformation; enzyme activity; enzyme complex; enzyme inhibitors; enzyme mechanism; fibrin; gene mutation; heparin; ionic bond; mucopolysaccharides; protein binding; protein structure function; serine proteinases; structural biology; thrombin; thrombosis

DESCRIPTION (provided by applicant): The long-term goal of this research is to understand the three natural mechanisms which control the activity of thrombin, the final protease of the blood coagulation cascade: 1) prevention of thrombin formation through inhibition of upstream coagulation factor Xa; 2) direct inhibition of thrombin by serpins antithrombin (AT) and heparin cofactor II (HCII); and, 3) attenuation of thrombin's procoagulant activity through cofactor binding and allosteric modulation. This will be achieved by completing the following five specific aims (SA): SA1-To determine the crystal structures of the Michaelis complexes between AT and factor Xa will define the molecular basis of AT recognition of factor Xa, the protease responsible for thrombin formation. We will solve the crystal structures of the Michaelis complexes between AT and factor Xa in the absence and presence of heparin by creating variants of AT and factor Xa designed to improve crystallization or to increase the stability of the complex to improve the likelihood of success. SA2-To determine the heparin binding mechanism of AT addresses fundamental questions concerning the basis of heparin binding specificity of AT, by determining: a) how AT interacts with low-affinity heparin; b) high resolution crystal structures of AT bound to low and high- affinity heparin and pentasaccharides; c) crystal structures of monomeric native and activated AT; d) the role of hinge region expulsion in heparin binding; and, e) the role of electrostatics in propagating the conformational change. SA3-To determine the structures of native and oligosaccharide-activated HCII will define how heparin activates thrombin inhibition by HCII. Successful completion of this aim will elucidate the molecular mechanism of HCII activation, and will aid in the development of a novel class of anti-thrombin agents HCII agonists. SA4-To determine the molecular basis of thrombin allostery investigates how thrombin activity can be altered by conformational changes induced by binding to TM or to the monovalent cation Na+, by determining the crystallographic structures of TM-bound (active site-free) thrombin, and the Na+-free ('slow') form of thrombin. Structures will be validated in solution using 2D NMR techniques. The combined crystallographic and solution NMR approach will establish, once-and-for-all, the molecular basis of thrombin allostery. SA5-To determine the Na+ binding properties of thrombin investigates the potential relevance of Na+-allostery, which depends on the affinity of thrombin for Na+ under physiological conditions. Titration studies will accurately determine the effect of temperature, ionic strength, ion type, pH, and albumin concentration on the apparent Kd of thrombin for Na+, in order to establish the potential relevance of Na+ allostery in blood coagulation. Successful completion of these five aims will significantly improve our understanding of the natural mechanisms which limit the activity of thrombin, and could lead to the development of novel therapeutic approaches for the prevention and treatment of thrombosis-a leading cause of morbidity and death in the United States, and the rest of the developed world.

描述（由申请人提供）：本研究的长期目标是了解控制凝血酶（凝血级联的最终蛋白酶）活性的三种自然机制：1）通过抑制上游凝血因子Xa来预防凝血酶形成； 2)丝氨酸蛋白酶抑制剂抗凝血酶(AT)和肝素辅因子II(HCII)直接抑制凝血酶； 3) 通过辅因子结合和变构调节减弱凝血酶的促凝血活性。这将通过完成以下五个具体目标 (SA) 来实现： SA1-确定 AT 和 Xa 因子之间米氏复合物的晶体结构将定义 AT 识别 Xa 因子（负责凝血酶形成的蛋白酶）的分子基础。我们将通过创建 AT 和 Xa 因子的变体来解决 AT 和 Xa 因子之间的米氏复合物在肝素不存在和存在的情况下的晶体结构，这些变体旨在改善结晶或增加复合物的稳定性，从而提高成功的可能性。 SA2-确定 AT 的肝素结合机制，通过确定以下内容解决有关 AT 肝素结合特异性基础的基本问题： a) AT 如何与低亲和力肝素相互作用； b) 与低亲和力和高亲和力肝素和五糖结合的 AT 的高分辨率晶体结构； c)单体天然和活化AT的晶体结构； d) 铰链区排出在肝素结合中的作用； e) 静电在传播构象变化中的作用。 SA3-确定天然和寡糖激活的 HCII 的结构将确定肝素如何激活 HCII 的凝血酶抑制作用。这一目标的成功完成将阐明 HCII 激活的分子机制，并将有助于开发一类新型抗凝血酶药物 HCII 激动剂。 SA4-确定凝血酶变构的分子基础，通过确定 TM 结合（无活性位点）凝血酶和无 Na+（“慢速”）形式凝血酶的晶体结构，研究凝血酶活性如何通过与 TM 或单价阳离子 Na+ 结合诱导的构象变化而改变。将使用二维核磁共振技术在溶液中验证结构。结合晶体学和溶液核磁共振方法将一劳永逸地建立凝血酶变构的分子基础。 SA5-为了确定凝血酶的 Na+ 结合特性，研究了 Na+-变构的潜在相关性，这取决于生理条件下凝血酶对 Na+ 的亲和力。滴定研究将准确确定温度、离子强度、离子类型、pH 和白蛋白浓度对 Na+ 凝血酶表观 Kd 的影响，从而确定 Na+ 变构在血液凝固中的潜在相关性。成功实现这五个目标将显着提高我们对限制凝血酶活性的自然机制的理解，并可能导致开发预防和治疗血栓形成的新治疗方法，血栓形成是美国和其他发达国家发病和死亡的主要原因。